MARKET

CBAY

CBAY

CymaBay
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.740
-0.010
-0.57%
Closed 18:59 12/09 EST
OPEN
1.770
PREV CLOSE
1.750
HIGH
1.835
LOW
1.675
VOLUME
2.41M
TURNOVER
--
52 WEEK HIGH
14.00
52 WEEK LOW
1.290
MARKET CAP
119.54M
P/E (TTM)
-1.2147
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CBAY and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 10 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

CBAY News

  • Should You Take Comfort From Insider Transactions At CymaBay Therapeutics, Inc. (NASDAQ:CBAY)?
  • Simply Wall St..22h ago
  • Is CymaBay Therapeutics Inc (CBAY) Going To Burn These Hedge Funds ?
  • Insider Monkey.1d ago
  • The Zacks Analyst Blog Highlights: Intercept, CymaBay, Amgen, Global Blood Therapeutics and ChemoCentryx
  • Zacks.11/29 16:24
  • NASH Scorecard Year to Date: The Winners and the Losers
  • Zacks.11/29 13:41

More

Industry

Biotechnology & Medical Research
+0.51%
Pharmaceuticals & Medical Research
+0.23%

Hot Stocks

Name
Price
%Change

About CBAY

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company's product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout. MBX-8025 is a selective agonist for the peroxisome proliferator-activated receptor delta (PPARd). The Company has completed over five Phase I clinical studies and a Phase II clinical study for MBX-8025. MBX-2982 is an oral, G-protein coupled receptor agonist being evaluated as a therapeutic agent for patients with Type 2 diabetes (T2DM), with a dual mechanism, including direct effects and indirect effects mediated by gastrointestinal hormones known as incretins on glucose-dependent insulin secretion, as well as potentially beneficial effects on islet health. The Company has completed over four Phase I clinical studies and a Phase II clinical study for MBX-2982.
More

Webull offers CymaBay Therapeutics Inc (CBAY) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.